Provectus Biopharmaceuticals I - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
PVCT Over the counter 2834 http://www.provectusbio.com/ 0.0247 Stock Up +0.0007

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Provectus Biopharmaceuticals I

Provectus Biopharmaceuticals Reestablishes Strategic Advisory Board - Apr 20th, 2017 2:15 pm
Provectus Biopharmaceuticals Closes Definitive Financing With PRH Group - Apr 4th, 2017 4:00 am
Provectus Biopharmaceuticals Announces Terms Of Definitive Financing Commitment - Mar 23rd, 2017 3:55 pm
Provectus Biopharmaceuticals Enters Into Definitive Financing Commitment Term Sheet - Mar 20th, 2017 6:50 am
Provectus Biopharmaceuticals, Inc. Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In Provectus - Mar 6th, 2017 4:01 am
Provectus Biopharmaceuticals Provides Information On Rights Offering Deadline - Feb 24th, 2017 6:33 am
Provectus Biopharmaceuticals Appoints Bruce Horowitz And Dominic Rodrigues As Special Advisers To The Board Of Directors - Feb 23rd, 2017 7:03 am
Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering - Feb 10th, 2017 4:44 pm
Provectus Biopharmaceuticals, Inc. Announces Commencement Of Rights Offering To Existing Stockholders And Holders Of Certain Warrants - Jan 31st, 2017 6:00 am
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO - Dec 28th, 2016 3:15 pm
CORRECTING and REPLACING Provectus Biopharmaceuticals Announces Two Poster Presentations on PV-10 for Liver Tumors - Dec 22nd, 2016 9:11 am
Provectus Biopharmaceuticals Announces Agreement with POETIC (Pediatric Oncology Experimental Therapeutics Investigators Consortium) to Study Potential of PV-10 for Pediatric Cancer - Dec 8th, 2016 4:00 am
Provectus Biopharmaceuticals, Inc. Announces Notification of NYSE MKT Listing Deficiency - Nov 30th, 2016 2:05 pm
Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 at Society for Immunotherapy of Cancer 2016 Annual Meeting - Nov 14th, 2016 4:00 am
Provectus Biopharmaceuticals Reports Third Quarter 2016 Financial Results - Nov 10th, 2016 3:15 pm
Provectus Biopharmaceuticals Announces Data on PV-10 for Treatment of Pancreatic Cancer Scheduled for Poster Presentation at 31st SITC Annual Meeting - Nov 2nd, 2016 4:00 am
Provectus Biopharmaceuticals Will Hold Its 2016 Third Quarter Business Update Conference Call on Monday, November 14, 2016, at 4 PM Eastern Standard Time - Oct 25th, 2016 4:00 am
Trading in Provectus Biopharmaceuticals Common Stock and Warrants Suspended by NYSE MKT - Oct 14th, 2016 3:38 pm
Provectus Biopharmaceuticals Files Registration Statement for Rights Offering to Existing Stockholders - Oct 5th, 2016 3:47 pm